Drug intelligence / Profile preview

gD1-306-HD

Development stage
Preclinical
Lead developer
Molecular Express
Modality
Vaccines & Immunotherapeutics
Administration
Subcutaneous
01

Overview

gD1-306-HD is a preclinical liposomal vaccine candidate developed by Molecular Express for the prevention or treatment of Herpes Simplex Virus Type 2 (HSV-2) infection. Utilizing the company's proprietary VesiVax platform, the vaccine consists of a truncated HSV-2 glycoprotein D (gD) ectodomain antigen (residues 1-306) formulated within a liposomal delivery system that incorporates an adjuvant. The mechanism of action involves the presentation of the gD antigen to the immune system to elicit a robust neutralizing antibody and T-cell response against HSV-2. The VesiVax platform is designed to enhance the delivery of both the antigen and the adjuvant, potentially improving the immunogenicity and protective efficacy of the vaccine compared to traditional formulations.

Brand names
VesiVax HSV-2 Vaccine
Other names
VesiVax HSV-2 Vaccine
02

Targets

TLR4 (Toll-like receptor 4)NECTIN1 (Poliovirus receptor-related 1)gD (Herpes simplex virus 1 glycoprotein D)TMEFF2

Beyond the preview

Go deeper on gD1-306-HD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gD1-306-HD.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call